论文部分内容阅读
目的:观察辛伐他汀对大鼠实验性脂肝的影响。 方法:制备大鼠实验性脂肪肝模型;观察大鼠肝组织病理学变化;测定肝组织脂质过氧化物丙二醛和甘油三酯含量以及血清生化学指标。 结果:辛伐他汀治疗组大鼠肝组织脂肪肝形成程度减轻,肝细胞质内脂滴明显减少;肝组织甘油三酯和丙二醛含量下降,大剂量组为51.2±10mg/g和460±172nmol/L,小剂量组为49.2±3.5mg/g和502±160nmol/L,低于模型组的65.5±9.4mg/g和718±116nmol/L(P<0.05)。治疗组大鼠血清谷丙转氨酶较模型组降低(54.6±9U/L和55.0±7.0U/L,vs 69.0±5.5U/L,P<0.05)。 结论:辛伐他汀具有防治大鼠实验性脂肪肝的作用
Objective: To observe the effect of simvastatin on experimental fatty liver in rats. Methods: The rat model of experimental fatty liver was prepared. The pathological changes of rat liver were observed. The levels of lipid peroxides, malondialdehyde and triglyceride were determined and the serum biochemical indexes were determined. Results: The degree of hepatic fatty liver formation in simvastatin group was relieved and the amount of lipid droplets in hepatic cytoplasm was significantly reduced. The content of triglyceride and malondialdehyde in liver tissue was decreased in high-dose group and was 51.2 ± 10 mg / g and 460 ± 172 nmol / L, 49.2 ± 3.5 mg / g and 502 ± 160 nmol / L in the low-dose group, which was lower than 65.5 ± 9.4 mg / g and 718 ± 116 nmol / L in the model group (P <0.05). Serum alanine aminotransferase (ALT) in treatment group was lower than that in model group (54.6 ± 9U / L and 55.0 ± 7.0U / L, vs 69.0 ± 5.5U / L, P <0.05). Conclusion: Simvastatin can prevent and cure experimental fatty liver in rats